Abudayyeh is among the many researchers and companies racing to develop new and speedier types of diagnostic tests that circumvent clinical labs altogether.Abudayyeh was previously at Harvard Medical School and co-led the discovery and characterization of Cpf1 for novel genome editing applications and the first single-protein RNA-guided RNA-targeting enzyme C2c2/Cas13.Abudayyeh, Gootenberg, and Zhang are co-founders, scientific advisors, and hold equity interests in Sherlock Biosciences, Inc.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
In general, LAMP-based diagnostic tests aren’t quite as sensitive as ones based on PCR, Tanner says, but could be used to test more people, given their simpler requirements. An antigen test by Abbott Laboratories requires only a test card, a swab sample and a few drops of a reaction solution to return a COVID-19 diagnosis in 15 minutes. With overwhelming demand for COVID-19 testing, it can take days or even longer than a week for people to receive test results.
A team of researchers at the McGovern Institute for Brain Research at MIT, the Broad Institute of MIT and Harvard, the Ragon Institute, and the Howard Hughes Medical Institute has developed a new diagnostics platform called STOP. In research, it has been shown to enable rapid, accurate, and highly sensitive detection of the Covid-19 virus SARS-CoV-2, with a simple protocol that requires minimal training and uses simple, readily available equipment, such as test tubes and water baths.